ARTIK-52 induces replication-dependent DNA damage and p53 activation exclusively in cells of prostate and breast cancer origin

References

• Tararova ND, Narizhneva N, Krivokrisenko V, Gudkov AV, Gurova KV. Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity. Prostate 2007; 67:1801-15; PMID:17935158; http://dx.doi.org/10.1002/pros.20662
   PubMed Web of Science ®Google Scholar
• Narizhneva NV, Tararova ND, Ryabokon P, Shyshynova I, Prokvolit A, Komarov PG, Purmal AA, Gudkov AV, Gurova KV. Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer. Cell Cycle 2009; 8:4155-67; PMID:19946220; http://dx.doi.org/10.4161/cc.8.24.10316
   PubMed Web of Science ®Google Scholar
• Chen CY, Gherzi R, Ong SE, Chan EL, Raijmakers R, Pruijn GJ, Stoecklin G, Moroni C, Mann M, Karin M. AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell 2001; 107:451-64; PMID:11719186; http://dx.doi.org/10.1016/S0092-8674(01)00578-5
   PubMed Web of Science ®Google Scholar
• Sikand K, Slaibi JE, Singh R, Slane SD, Shukla GC. miR 488* inhibits androgen receptor expression in prostate carcinoma cells. Inter J Cancer 2011; 129:810-9; PMID:21710544; http://dx.doi.org/10.1002/ijc.25753
   PubMed Web of Science ®Google Scholar
• Provost P, Dishart D, Doucet J, Frendewey D, Samuelsson B, Radmark O. Ribonuclease activity and RNA binding of recombinant human Dicer. EMBO J 2002; 21:5864-74; PMID:12411504; http://dx.doi.org/10.1093/emboj/cdf578
   PubMed Web of Science ®Google Scholar
• Yeap BB, Wilce JA, Leedman PJ. The androgen receptor mRNA. Bio Essays 2004; 26:672-82; PMID:15170865; http://dx.doi.org/10.1002/bies.20051
   PubMed Web of Science ®Google Scholar
• Yeap BB, Voon DC, Vivian JP, McCulloch RK, Thomson AM, Giles KM, Czyzyk-Krzeska MF, Furneaux H, Wilce MC, Wilce JA, et al. Novel binding of HuR and poly(C)-binding protein to a conserved UC-rich motif within the 3'-untranslated region of the androgen receptor messenger RNA. J Biol Chem 2002; 277:27183-92; PMID:12011088; http://dx.doi.org/10.1074/jbc.M202883200
   PubMed Web of Science ®Google Scholar
• Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem 2009; 284:24696-704; PMID:19584056; http://dx.doi.org/10.1074/jbc.M109.030098
   PubMed Web of Science ®Google Scholar
• Epis MR, Barker A, Giles KM, Beveridge DJ, Leedman PJ. The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem 2011; 286:41442-54; PMID:21971048; http://dx.doi.org/10.1074/jbc.M111.301481
   PubMed Web of Science ®Google Scholar
• Yeap BB, Krueger RG, Leedman PJ. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology 1999; 140:3282-91; PMID:10385425
   PubMed Web of Science ®Google Scholar
• Safarpour D, Tavassoli FA. A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. Arch Pathol Laborat Med 2014; PMID:25310144
   PubMed Web of Science ®Google Scholar
• McNamara KM, Moore NL, Hickey TE, Sasano H, Tilley WD. Complexities of androgen receptor signalling in breast cancer. Endocr Relat Cancer 2014; 21:T161-81; PMID:24951107; http://dx.doi.org/10.1530/ERC-14-0243
   PubMed Web of Science ®Google Scholar
• Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A 2012; 109:2724-9; PMID:22003129; http://dx.doi.org/10.1073/pnas.1018854108
   PubMed Web of Science ®Google Scholar
• Bennett N, Hooper JD, Lee CS, Gobe GC. Androgen receptor and caveolin-1 in prostate cancer. IUBMB Life 2009; 61:961-70; PMID:19787702; http://dx.doi.org/10.1002/iub.244
   PubMed Web of Science ®Google Scholar
• Marquez B, Van Bambeke F. ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. Curr Drug Targets 2011; 12:600-20; PMID:21039335; http://dx.doi.org/10.2174/138945011795378504
   PubMed Web of Science ®Google Scholar
• Sheikh KD, Khanna S, Byers SW, Fornace A, Jr., Cheema AK. Small molecule metabolite extraction strategy for improving LC/MS detection of cancer cell metabolome. J Biomol Tech 2011; 22:1-4; PMID:21455475
   PubMedGoogle Scholar
• Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer 2006; 13:293-325; PMID:16728565; http://dx.doi.org/10.1677/erc.1.01172
   PubMed Web of Science ®Google Scholar
• Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, Saranadasa M, Bosykh DA, Commane M, Guryanova OA, Pal S, et al. Curaxins: anticancer compounds that simultaneously suppress NF-kappaB and activate p53 by targeting FACT. Sci Trans Med 2011; 3:95ra74; PMID:21832239; http://dx.doi.org/10.1126/scitranslmed.3002530
   PubMed Web of Science ®Google Scholar
• Liu T, Li Y, Gu H, Zhu G, Li J, Cao L, Li F. p21-Activated kinase 6 (PAK6) inhibits prostate cancer growth via phosphorylation of androgen receptor and tumorigenic E3 ligase murine double minute-2 (Mdm2). J Biol Chem 2013; 288:3359-69; PMID:23132866; http://dx.doi.org/10.1074/jbc.M112.384289
   PubMed Web of Science ®Google Scholar
• Gaughan L, Logan IR, Neal DE, Robson CN. Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucl Acids Res 2005; 33:13-26; PMID:15640443; http://dx.doi.org/10.1093/nar/gki141
   PubMed Web of Science ®Google Scholar
• Ossovskaya VS, Mazo IA, Chernov MV, Chernova OB, Strezoska Z, Kondratov R, Stark GR, Chumakov PM, Gudkov AV. Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc Natl Acad Sci U S A 1996; 93:10309-14; PMID:8816796; http://dx.doi.org/10.1073/pnas.93.19.10309
   PubMed Web of Science ®Google Scholar
• Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM, Choubey D. Expression of androgen receptor is negatively regulated by p53. Neoplasia 2007; 9:1152-9; PMID:18084622; http://dx.doi.org/10.1593/neo.07769
   PubMed Web of Science ®Google Scholar
• Iyama T, Wilson DM, 3rd. DNA repair mechanisms in dividing and non-dividing cells. DNA Repair 2013; 12:620-36; PMID:23684800; http://dx.doi.org/10.1016/j.dnarep.2013.04.015
   PubMed Web of Science ®Google Scholar
• Bhuyan BK, Fraser TJ, Gray LG, Kuentzel SL, Neil GL. Cell-kill kinetics of several S-phase-specific drugs. Cancer Res 1973; 33:888-94; PMID:4735241
   PubMed Web of Science ®Google Scholar
• Caldecott KW. XRCC1 and DNA strand break repair. DNA Repair 2003; 2:955-69; PMID:12967653; http://dx.doi.org/10.1016/S1568-7864(03)00118-6
   PubMed Web of Science ®Google Scholar
• Missura M, Buterin T, Hindges R, Hubscher U, Kasparkova J, Brabec V, Naegeli H. Double-check probing of DNA bending and unwinding by XPA-RPA: an architectural function in DNA repair. EMBO J 2001; 20:3554-64; PMID:11432842; http://dx.doi.org/10.1093/emboj/20.13.3554
   PubMed Web of Science ®Google Scholar
• Wold MS. Replication protein A: a heterotrimeric, single-stranded DNA-binding protein required for eukaryotic DNA metabolism. Annu Rev Biochem 1997; 66:61-92; PMID:9242902; http://dx.doi.org/10.1146/annurev.biochem.66.1.61
   PubMed Web of Science ®Google Scholar
• Feng W, Di Rienzi SC, Raghuraman MK, Brewer BJ. Replication stress-induced chromosome breakage is correlated with replication fork progression and is preceded by single-stranded DNA formation. G3 2011; 1:327-35; PMID:22384343; http://dx.doi.org/full_text
   PubMed Web of Science ®Google Scholar
• Rigatti MJ, Verma R, Belinsky GS, Rosenberg DW, Giardina C. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells. Mol Carcinogen 2012; 51:363-78; PMID:21557332; http://dx.doi.org/10.1002/mc.20795
   PubMed Web of Science ®Google Scholar
• Zheng W, Thorne N, McKew JC. Phenotypic screens as a renewed approach for drug discovery. Drug Dis Today 2013; 18:1067-73; PMID:23850704; http://dx.doi.org/10.1016/j.drudis.2013.07.001
   PubMed Web of Science ®Google Scholar
• Lee JA, Shinn P, Jaken S, Oliver S, Willard FS, Heidler S, Peery RB, Oler J, Chu S, Southall N, et al. Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays. PloS One 2015; 10:e0130796; PMID:26177200; http://dx.doi.org/10.1371/journal.pone.0130796
   PubMed Web of Science ®Google Scholar
• Eder J, Sedrani R, Wiesmann C. The discovery of first-in-class drugs: origins and evolution. Nat Rev Drug Dis 2014; 13:577-87; PMID:25033734; http://dx.doi.org/10.1038/nrd4336
   PubMed Web of Science ®Google Scholar
• Moffat JG, Rudolph J, Bailey D. Phenotypic screening in cancer drug discovery - past, present and future. Nat Rev Drug Dis 2014; 13:588-602; PMID:25033736; http://dx.doi.org/10.1038/nrd4366
   PubMed Web of Science ®Google Scholar
• Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, Arora VK, Yen WF, Cai L, Zheng D, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Dis 2013; 3:1245-53; PMID:24027196; http://dx.doi.org/10.1158/2159-8290.CD-13-0172
   PubMed Web of Science ®Google Scholar
• Wang L, Hsu CL, Ni J, Wang PH, Yeh S, Keng P, Chang C. Human checkpoint protein hRad9 functions as a negative coregulator to repress androgen receptor transactivation in prostate cancer cells. Mol Cell Biol 2004; 24:2202-13; PMID:14966297; http://dx.doi.org/10.1128/MCB.24.5.2202-2213.2004
   PubMed Web of Science ®Google Scholar
• Ta HQ, Gioeli D. The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer. Endocr Related Cancer 2014; 21:R395-407; PMID:25096064; http://dx.doi.org/10.1530/ERC-14-0217
   PubMed Web of Science ®Google Scholar
• Yeh S, Hu YC, Rahman M, Lin HK, Hsu CL, Ting HJ, Kang HY, Chang C. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc Natl Acad Sci U A 2000; 97:11256-61; PMID:11016951; http://dx.doi.org/10.1073/pnas.190353897
   PubMed Web of Science ®Google Scholar
• Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, Stallcup MR, Press MF, Coetzee GA. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res 2000; 60:5946-9; PMID:11085509
   PubMed Web of Science ®Google Scholar
• Shin S, Verma IM. BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription. Proc Natl Acad Sci U S A 2003; 100:7201-6; PMID:12756300; http://dx.doi.org/10.1073/pnas.1132020100
   PubMed Web of Science ®Google Scholar
• Wo JY, Zietman AL. Why does androgen deprivation enhance the results of radiation therapy? Urologic Oncol 2008; 26:522-9; PMID:18774467; http://dx.doi.org/10.1016/j.urolonc.2008.03.008
   PubMed Web of Science ®Google Scholar
• Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994; 368:258-61; PMID:8145827; http://dx.doi.org/10.1038/368258a0
   PubMed Web of Science ®Google Scholar
• Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1994; 77:1 p following 166; PMID:8156592; http://dx.doi.org/10.1016/0092-8674(94)90226-7
   PubMed Web of Science ®Google Scholar
• Beiner ME, Rosen B, Fyles A, Harley I, Pal T, Siminovitch K, Zhang S, Sun P, Narod SA. Endometrial cancer risk is associated with variants of the mismatch repair genes MLH1 and MSH2. Cancer Epidemiol Biomarkers Prev 2006; 15:1636-40; PMID:16985024; http://dx.doi.org/10.1158/1055-9965.EPI-06-0257
   PubMed Web of Science ®Google Scholar
• Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology 2010; 138:2044-58; PMID:20420945; http://dx.doi.org/10.1053/j.gastro.2010.01.054
   PubMed Web of Science ®Google Scholar
• Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71; PMID:7545954; http://dx.doi.org/10.1126/science.7545954
   PubMed Web of Science ®Google Scholar
• Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250:1684-9; PMID:2270482; http://dx.doi.org/10.1126/science.2270482
   PubMed Web of Science ®Google Scholar
• Maia S, Cardoso M, Paulo P, Pinheiro M, Pinto P, Santos C, Pinto C, Peixoto A, Henrique R, Teixeira MR. The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer. Familial Cancer 2015; PMID:26289772
   PubMed Web of Science ®Google Scholar
• Goldgar DE, Neuhausen SL, Steele L, Fields P, Ward JH, Tran T, Ngyuen K, Stratton MR, Easton DF. A 45-year follow-up of kindred 107 and the search for BRCA2. J Natl Cancer Inst Monogr 1995:15-9; PMID:8573446
   PubMedGoogle Scholar
• Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res 2004; 64:1951-8; PMID:15026329; http://dx.doi.org/10.1158/0008-5472.CAN-03-1541
   PubMed Web of Science ®Google Scholar